Compounds > staurosporine
Page last updated: 2024-08-23

staurosporine and Granulocytic Leukemia, Chronic

staurosporine has been researched along with Granulocytic Leukemia, Chronic in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (44.44)18.2507
2000's0 (0.00)29.6817
2010's4 (44.44)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Abbe, P; Benhida, R; Cavazza, E; Cerezo, M; Jaune, E; Millet, A; Plaisant, M; Rocchi, S; Ronco, C1
Bang, EK; El-Damasy, AK; Jin, H; Keum, G; Seo, SH1
Manley, PW1
Fang, Q; He, Z; Lu, T; Ma, D; Wang, J; Wang, P; Wei, D; Yu, K; Yu, Z; Zhang, Y; Zhou, Z1
Barbui, T; Bose, P; Chen, CC; Deininger, MW; Gotlib, J; Kiladjian, JJ; Koschmieder, S; Kucine, N; Mughal, TI; Pemmaraju, N; Radich, JP; Rampal, R; Saglio, G; Valent, P; Van Etten, RA; Verstovsek, S1
Golde, DW; Lacomis, L; Nichols, GL; Raines, MA; Tempst, P; Vera, JC1
Chorvath, B; Duraj, J; Hunakova, L; Novotny, L; Sedlak, J1
Platko, JD; Varvayanis, S; Yen, A1
Savage, N; Weitzmann, MN1

Reviews

1 review(s) available for staurosporine and Granulocytic Leukemia, Chronic

ArticleYear
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms.
    Hematological oncology, 2019, Volume: 37, Issue:3

    Topics: Aging; Animals; Congresses as Topic; DNA Mutational Analysis; Humans; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Medical Oncology; Mice; Mutation; Myeloproliferative Disorders; Prognosis; Societies, Medical; Staurosporine; Translational Research, Biomedical; United States

2019

Other Studies

8 other study(ies) available for staurosporine and Granulocytic Leukemia, Chronic

ArticleYear
Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells.
    Journal of medicinal chemistry, 2016, 09-22, Volume: 59, Issue:18

    Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Mice; Pancreatic Neoplasms; Structure-Activity Relationship; Thiazoles

2016
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    European journal of medicinal chemistry, 2020, Dec-01, Volume: 207

    Topics: Amination; Antineoplastic Agents; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; Indazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Protein Kinase Inhibitors

2020
Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin.
    Chimia, 2019, Aug-21, Volume: 73, Issue:7

    Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Staurosporine

2019
Low-dose staurosporine selectively reverses BCR-ABL-independent IM resistance through PKC-α-mediated G2/M phase arrest in chronic myeloid leukaemia.
    Artificial cells, nanomedicine, and biotechnology, 2018, Volume: 46, Issue:sup3

    Topics: Animals; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; G2 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase C-alpha; Staurosporine; Xenograft Model Antitumor Assays

2018
Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
    Blood, 1994, Nov-01, Volume: 84, Issue:9

    Topics: Adaptor Proteins, Signal Transducing; Alkaloids; Amino Acid Sequence; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Molecular Weight; Neutrophils; Nuclear Proteins; Phosphoproteins; Phosphorylation; Phosphotyrosine; Staurosporine; Tyrosine

1994
Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines.
    Anti-cancer drugs, 1995, Volume: 6, Issue:1

    Topics: Alkaloids; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Cycle; Cytarabine; DNA Replication; DNA, Neoplasm; Drug Resistance, Multiple; Drug Synergism; Female; Humans; Leukemia L1210; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred DBA; Neoplasm Proteins; Ovarian Neoplasms; Protein Kinase C; Staurosporine; Tumor Cells, Cultured

1995
12-O-tetradecanoylphorbol-13-acetate and staurosporine induce increased retinoblastoma tumor suppressor gene expression with megakaryocytic differentiation of leukemic cells.
    Cancer research, 1993, Jul-01, Volume: 53, Issue:13

    Topics: Alkaloids; Cell Cycle; Cell Differentiation; DNA, Neoplasm; Gene Expression; Gene Expression Regulation, Leukemic; Genes, Retinoblastoma; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Phosphorylation; Protein Kinase C; Retinoblastoma Protein; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured

1993
Cyclic adenosine 3',5'-monophosphate, a second messenger in interleukin-1 mediated K562 cytostasis.
    Biochemical and biophysical research communications, 1993, Jan-29, Volume: 190, Issue:2

    Topics: Adenylyl Cyclases; Alkaloids; Bucladesine; Cell Division; Colforsin; Cyclic AMP; Humans; Interleukin-1; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Second Messenger Systems; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured

1993